Therefore, compounds targeting TRAF6 interactions with CD40, which have proven beneficial in animal models of experimental peritonitis and sepsis33, may be an attractive target for the prevention of inflammatory and infectious complications in advanced cirrhosis. Here, TRAF6 is linked to peritonitis.